Regulating Off-Label Promotion - A Critical Test.
From the Regulatory Science Program and James E. Rogers College of Law, University of Arizona, Tucson (C.R.); New York University School of Law, New York (C.R.); and the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (A.S.K.).
Christopher
C
Robertson
From the Regulatory Science Program and James E. Rogers College of Law, University of Arizona, Tucson (C.R.); New York University School of Law, New York (C.R.); and the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (A.S.K.).
Aaron S
AS
Kesselheim
D002961:Civil Rights / Q000331:legislation & jurisprudence*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D033161:Government Regulation; D006801:Humans; D007880:Legislation, Drug; D040541:Marketing / Q000331:legislation & jurisprudence*; D056687:Off-Label Use / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence